A Phase 1 clinical trial is evaluating an investigational vaccine designed to protect against coronavirus disease in Seattle.
The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccineon Monday, March 16th.
The study is evaluating different doses of the experimental vaccine for safety, and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine.
The investigational vaccine was developed using a genetic platform called mRNA. The investigational vaccine directs the body’s cells to express a virus protein that it is hoped will elicit a robust immune response.
The mRNA-1273 vaccine has shown promising results in animal models, and this is the first tiem it will be used on humans.
Comments
more recommended stories
Shootings, fires, and blockades, at least 3 injured in Matamoros, TamaulipasIn Matamoros, Tamaulipas, México a series.
Oaxaca Giant ‘Alebrijes’, conquer New York City with their magicThe giant alebrijes placed in New.
Bomb Cyclone – Atmospheric River coming to blast the Western USA series of potent storms is.
Demand for security in Tulum increases after the death of touristsCitizens demand an end to the.
María José relatives demand justice in front of the Yucatán Government PalaceThe relatives of Maria Jose demanded.
INEGI reports annual inflation of 6.12%, AMLO says it is temporary and there will be no peso devaluation“The peso is in very good.
Cancun commemorates the 10th anniversary of the Paris-Cancun air routeCancun, Quintana Roo, (October 22, 2021).-.
UANL stands as the most sustainable university in all of MexicoThe Autonomous University of Nuevo León.
Evo Morales thanks Mexico for “saving his life” 2 years agoMEXICO, (October 22, 2021).- Almost two.
Biden under pressure as U.S.-Mexico border registers illegal immigration record figuresOctober 22, 2021, (Reuters) – U.S..
Leave a Comment